Compare Novo Nordisk A/S (NVO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ryanair Holdings plc — how do they compare? Novo Nordisk A/S trades at $38.55 (market cap $165.31B), while Ryanair Holdings plc trades at $53.5 (market cap $27.11B). The key difference: Novo Nordisk A/S is far larger — about 6.1× Ryanair Holdings plc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Ryanair Holdings plc for 72 Days on average.
| NVO | RYAAY | |
|---|---|---|
Market Cap | $165.31B | $27.11B |
Volume | 11,432,838 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $63.98 | $73.82 |
52-Week Low | $35.29 | $51.95 |
Typical Hold Time | 116 Days | 72 Days |
Enterprise Value | $179.56B | $24.18B |
Dividend Yield | 4.71% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
RYAAY trades at $53.05, down 5.27% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at 13.43 P/E. Recent earnings show mixed results with Q2 2026 missing expectations, while analysts maintain 64.71% buy rating. The company faces headwinds from fuel costs and Boeing MAX 10 certification delays, but maintains robust cash flow and balance sheet strength.
RYAAY presents a compelling value opportunity with solid profitability and growth prospects, though near-term volatility from oil prices and operational challenges warrants caution. The stock's current discount to historical valuations combined with strong market position supports long-term upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
